Literature DB >> 19878656

Lrrk2 interaction with alpha-synuclein in diffuse Lewy body disease.

Hong Qing1, Yanyan Zhang, Yulin Deng, E G McGeer, P L McGeer.   

Abstract

Mutations of the leucine-rich repeat kinase 2 (LRRK2) gene are the leading cause of genetically inherited Parkinson's disease (PD) and its more severe variant diffuse Lewy body disease (DLB). Pathological mutations in Lrrk2 are autosomal dominant, suggesting a gain of function. Mutations in alpha-synuclein also produce autosomal dominant disease. Here we report an interaction between Lrrk2 and alpha-synuclein in a series of diffuse Lewy body (DLB) cases and in an oxidative stress cell based assay. All five cases of DLB, but none of five controls, showed co-immunoprecipitation of Lrrk2 and alpha-synuclein in soluble brain extracts. Colocalization was also found in pathological deposits in DLB postmortem brains by double immunostaining. In HEK cells transfected simultaneously with plasmids expressing Lrrk2 and alpha-synuclein, co-immunoprecipitation of Lrrk2 and alpha-synuclein was detected when they were exposed to oxidative stress by H(2)O(2). Taken together, these results suggest the possibility that in PD and related synucleinopathies, oxidative stress upregulates alpha-syn and Lrrk2 expression, paving the way for pathological interactions. New therapeutic approaches to PD and the synucleinopathies may result from limiting the interaction between Lrrk2 and alpha-synuclein.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19878656     DOI: 10.1016/j.bbrc.2009.10.126

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  16 in total

1.  Lrrk2 localization in the primate basal ganglia and thalamus: a light and electron microscopic analysis in monkeys.

Authors:  H Lee; H L Melrose; M Yue; Jean-Francois Pare; M J Farrer; Y Smith
Journal:  Exp Neurol       Date:  2010-05-17       Impact factor: 5.330

Review 2.  LRRK2, a puzzling protein: insights into Parkinson's disease pathogenesis.

Authors:  A Raquel Esteves; Russell H Swerdlow; Sandra M Cardoso
Journal:  Exp Neurol       Date:  2014-06-04       Impact factor: 5.330

3.  The genetic contributions of SNCA and LRRK2 genes to Lewy Body pathology in Alzheimer's disease.

Authors:  Colton Linnertz; Michael W Lutz; John F Ervin; Jawara Allen; Natalie R Miller; Kathleen A Welsh-Bohmer; Allen D Roses; Ornit Chiba-Falek
Journal:  Hum Mol Genet       Date:  2014-04-28       Impact factor: 6.150

Review 4.  Current understanding of LRRK2 in Parkinson's disease: biochemical and structural features and inhibitor design.

Authors:  Soumya Ray; Min Liu
Journal:  Future Med Chem       Date:  2012-09       Impact factor: 3.808

Review 5.  ERKed by LRRK2: a cell biological perspective on hereditary and sporadic Parkinson's disease.

Authors:  Manish Verma; Erin K Steer; Charleen T Chu
Journal:  Biochim Biophys Acta       Date:  2013-11-10

6.  Leucine-rich repeat kinase 2 and alpha-synuclein: intersecting pathways in the pathogenesis of Parkinson's disease?

Authors:  Elisa Greggio; Marco Bisaglia; Laura Civiero; Luigi Bubacco
Journal:  Mol Neurodegener       Date:  2011-01-18       Impact factor: 14.195

7.  Efficient allele-specific targeting of LRRK2 R1441 mutations mediated by RNAi.

Authors:  Laura de Yñigo-Mojado; Itziar Martín-Ruíz; James D Sutherland
Journal:  PLoS One       Date:  2011-06-21       Impact factor: 3.240

8.  Bridging molecular genetics and biomarkers in lewy body and related disorders.

Authors:  Gilbert J Ho; Willie Liang; Masaaki Waragai; Kazunari Sekiyama; Eliezer Masliah; Makoto Hashimoto
Journal:  Int J Alzheimers Dis       Date:  2011-07-03

Review 9.  Autophagy, mitochondria and oxidative stress: cross-talk and redox signalling.

Authors:  Jisun Lee; Samantha Giordano; Jianhua Zhang
Journal:  Biochem J       Date:  2012-01-15       Impact factor: 3.857

10.  α-synuclein, LRRK2 and their interplay in Parkinson's disease.

Authors:  Guoxiang Liu; Leonardo Aliaga; Huaibin Cai
Journal:  Future Neurol       Date:  2012-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.